<span item_type="fundamental" item_id="e76c7b5f8869d8e920a5f3634329df15" counter_id="ST/US/DERM" env="prod"></span><span item_type="announcement" item_id="648011611633945985" env="prod"></span><p>Revenue: As of FY2026 Q1, the actual value is USD 15.96 M, beating the estimate of USD 15.48 M.</p><p>EPS: As of FY2026 Q1, the actual value is USD -0.08.</p><p>EBIT: As of FY2026 Q1, the actual value is USD -443 K.</p><p></p><h3>Segment Revenue</h3><h4>Emrosi® Revenues</h4><ul><li>Emrosi® revenues were $6.3 million for the first quarter ended March 31, 2026, compared to $2.1 million for the same period in 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1867066/000110465926060232/tm2614268d1_ex99-1.htm"></span></li></ul><h4>Product Revenue, Net</h4><ul><li>Product revenue, net, was $15,921 thousand for the three-month period ended March 31, 2026, compared to $13,139 thousand for the same period in 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1867066/000110465926060232/tm2614268d1_ex99-1.htm"></span></li></ul><h4>Other Revenue</h4><ul><li>Other revenue was $40 thousand for the three-month period ended March 31, 2026, compared to $0 for the same period in 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1867066/000110465926060232/tm2614268d1_ex99-1.htm"></span></li></ul><h3>Operational Metrics</h3><h4>Gross Margin</h4><ul><li>Gross margin decreased to 61.0% for the first quarter of 2026, from 63.5% in the first quarter of 2025, primarily due to a - $1.3 million non-recurring non-cash charge against cost of goods associated with a write-down of API inventory.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1867066/000110465926060232/tm2614268d1_ex99-1.htm"></span></li></ul><h4>Selling, General and Administrative Expenses</h4><ul><li>Selling, general and administrative expenses decreased by - $0.5 million to $10.1 million for the three-month period ended March 31, 2026, from $10.6 million for the prior year quarter, mainly due to lower Emrosi® launch costs.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1867066/000110465926060232/tm2614268d1_ex99-1.htm"></span></li></ul><h4>Net Loss</h4><ul><li>Net loss for Journey Medical Corporation narrowed to - $2.2 million, or - $0.08 per share basic and diluted, for the first quarter of 2026, compared to a net loss of - $4.1 million, or - $0.18 per share basic and diluted, for the first quarter of 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1867066/000110465926060232/tm2614268d1_ex99-1.htm"></span></li></ul><h4>Loss from Operations</h4><ul><li>Loss from operations was - $1,492 thousand for the three-month period ended March 31, 2026, compared to - $3,324 thousand for the same period in 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1867066/000110465926060232/tm2614268d1_ex99-1.htm"></span></li></ul><h4>Non-GAAP Adjusted EBITDA</h4><ul><li>Non-GAAP Adjusted EBITDA was positive $0.6 million, or $0.02 per share basic and diluted, for the first quarter of 2026, compared to negative - $0.9 million, or - $0.04 loss per share basic diluted, for the first quarter of 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1867066/000110465926060232/tm2614268d1_ex99-1.htm"></span></li></ul><h4>Cost of Goods Sold (excluding amortization of acquired intangible assets)</h4><ul><li>Cost of goods sold (excluding amortization of acquired intangible assets) was $6,218 thousand for Q1 2026, up from $4,790 thousand for Q1 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1867066/000110465926060232/tm2614268d1_ex99-1.htm"></span></li></ul><h4>Amortization of Acquired Intangible Assets</h4><ul><li>Amortization of acquired intangible assets was $1,126 thousand for Q1 2026, compared to $1,065 thousand for Q1 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1867066/000110465926060232/tm2614268d1_ex99-1.htm"></span></li></ul><h4>Research and Development Expenses</h4><ul><li>Research and development expenses were $0 for Q1 2026, compared to $39 thousand for Q1 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1867066/000110465926060232/tm2614268d1_ex99-1.htm"></span></li></ul><h3>Cash Position</h3><ul><li>Cash and cash equivalents increased to $27.2 million at March 31, 2026, compared to $24.1 million at December 31, 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1867066/000110465926060232/tm2614268d1_ex99-1.htm"></span></li></ul><h3>Unique Metrics / Operational Highlights</h3><h4>Emrosi® Prescriptions</h4><ul><li>Emrosi® prescriptions totaled 29,968 for the first quarter of 2026, an increase from 27,023 in the fourth quarter of 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1867066/000110465926060232/tm2614268d1_ex99-1.htm"></span></li></ul><h4>Group Purchasing Organization (GPO) Contract</h4><ul><li>Journey Medical Corporation secured a contract with the third largest Group Purchasing Organization (GPO) in the United States for Emrosi® on April 21, 2026, expanding access to approximately 85% of all commercial lives in the nation.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1867066/000110465926060232/tm2614268d1_ex99-1.htm"></span></li></ul><h3>Outlook / Guidance</h3><ul><li>Journey Medical Corporation expects continued improvement in operating leverage, driven by net product sales growth and disciplined investment.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1867066/000110465926060232/tm2614268d1_ex99-1.htm"></span> The company anticipates that expanded payer access for Emrosi® will facilitate further growth in prescription demand.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1867066/000110465926060232/tm2614268d1_ex99-1.htm"></span> Journey Medical Corporation believes it is well-positioned to execute its strategy and deliver strong financial progress throughout the year, supported by its cash position and Emrosi®’s market performance.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1867066/000110465926060232/tm2614268d1_ex99-1.htm"></span></li></ul>

Journey Medical | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 15.96 M